BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023.
May 10, 2023 schedule:
4:05 p.m. ET – 2023 first quarter financial results press release will be distributed.
Prior to the call - To participate in the teleconference, go to the following link to register and the teleconference number and a pin number for the teleconference will be sent to you:
https://register.vevent.com/register/BI1408073fde3e47ab889cfdc791e65ccf
5:00 p.m. ET - Conference call and simultaneous webcast begins.
The conference call will also be available via webcast, and may be accessed on the investor relations page of OraSure’s website, www.orasure.com. Please click on the webcast link and follow the prompts for registration and access, 10 minutes prior to the call.
If you are unable to participate, the webcast will be archived on OraSure’s website shortly after the call has ended and will be available for 14 days.
| Investor Contact: | Media Contact: |
| Scott Gleason | Amy Koch |
| SVP Investor Relations & Corp. Communications | Director Corporate Communications |
| 484-425-0588 | 484-523-1815 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.34 |
| Daily Change: | -0.14 -4.02 |
| Daily Volume: | 894,191 |
| Market Cap: | US$244.290M |
February 25, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
